Oct. 24 at 10:43 AM
$OTLC The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer.
Well everyone should go study up on FDA approved “surrogate biomarkers” and with these surrogate biomarkers, clinical trials can be shortened … quickly stopped and approved all based upon surrogate biomarkers.
Enjoy